New shot aims to clear hepatitis b virus in chronic patients
NCT ID NCT07179653
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests an injection called TVAX-008 in 48 adults with chronic hepatitis B who have low levels of the virus. Half receive the drug, half a placebo, to see if it can clear a key virus marker (HBsAg) safely. The study is double-blind and already finished enrolling.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TVAX-008 injection
- What this could lead to
- If successful, this could point toward a way to clear hepatitis B surface antigen, potentially reducing long-term liver damage and the need for ongoing medication.
- What could go wrong
- This is an early Phase 2 trial with only 48 participants, so results may not apply broadly. The treatment may not achieve HBsAg clearance, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NanFang Hospital
Guangzhou, Guangdong, 20000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New injection aims to tame chronic hepatitis b
- Massive french study to track virus effects on pregnant women and kids for 7 years
- New blood test could spot liver cancer sooner
- Scientists map liver degeneration at the cellular level
- New hope for hepatitis b patients with normal ALT: TMF drug trial underway
- 5000 hepatitis b patients to be tracked for immune clues